Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098239 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL9128 | 0.97 | — | — | |
| SCHEMBL9077 | 0.92 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL4490456 | 0.92 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL3427016 | 0.92 | — | — | |
| SCHEMBL5857530 | 0.90 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1649755 | 0.90 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL378107 | 0.89 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL5256004 | 0.86 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL2092461 | 0.86 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 935 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | claimed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | claimed |
| EP-4166553-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | claimed |
| WO-1996033977-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | claimed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | claimed |
| US-5516915-A | Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | claimed |
| EP-0370236-B1 | INDOLOCARBAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0362695-B1 | PYRROLOCARBAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-04-03 | — | — | EP | claimed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | claimed |
| EP-0370236-A1 | Indolocarbazole derivatives, processes for their preparation and their use as medicaments | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0362695-A1 | Pyrrolocarbazole derivatives, processes for their preparation and their use as medicaments | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-04-11 | — | — | EP | claimed |
| US-4912107-A | Pyrrolocarbazole derivatives, compositions containing them, and methods for using them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1990-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | HRH3 3332/4885CYP1A2 3699/4885MAPK1 186/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | HRH3 3132/4885CYP1A2 933/4885MAPK1 46/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | HRH3 4383/4885CYP1A2 4025/4885MAPK1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.